Pharmaceutical News

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting...

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma to Present 17 Scientific Abstracts at AAD 2026...

CINCINNATI--(BUSINESS WIRE)--HealthWarehouse.com reported 2025 net sales of $49.0 million, a 46% increase over 2024, as partner services prescription revenues increased 87%....

AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T), a rare, progressive, inherited neurodegenerative disorder. This submission represents the first regulatory application submitted to the U.S. Food and Drug Administration seeking approval of a therapy for the treatment of Ataxia-Telangiectasia. The sNDA seeks...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, have been accepted for presentation at the 2026 Global Angioedema Leadership Conference taking place in Madrid, Spain from March 26–29, 2026. The following late-breaking abstract will be presented during the poster session on Friday, March 27 and as an oral presentation on Saturday, March 28 at 11:50 am CET: On-demand...

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it will take part in a workshop and present three posters at the upcoming SIRS 2026 Annual Congress taking place March 25-29, 2026, at the exhibition and congress area Firenze Fiera in Florence, Italy. Workshop Wednesday,...

PARIS--(BUSINESS WIRE)--Regulatory News: The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the first patients have been treated in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®.1 The REVISE...

WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology today announced a definitive agreement for Novartis to acquire Pikavation Therapeutics, Inc. (“Pikavation”) and its portfolio of PI3Kα inhibitor programs, including SNV4818. Pikavation is a wholly-owned subsidiary of Synnovation. SNV4818 is a potentially best-in-class pan-mutant sele...

CRYSTAL LAKE, Ill,--(BUSINESS WIRE)--Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray...

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-risk populations. The announcement is being made in time for World TB Day to underscore the continued importance of improving TB detection and prevention glo...